Last reviewed · How we verify

NCT06694051

Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism

Recruiting now NA Last updated 19 November 2024
What this trial tests

NA trial testing marking in Astigmatism in 100 participants. Currently enrolling.

Timeline
1 October 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorTianjin Eye Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 October 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Eye Hospital

Who can join

18 and older, any sex, with Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Corneal refractive surgery is an effective way to correct refractive error. Modern corneal refractive surgery for the correction of myopia or hyperopia can achieve or close to the expected goal, but to eliminate astigmatism is always one of the major problems of corneal refractive surgery. The key point in the correction of astigmatism is that as a vector parameter, astigmatism has both magnitude and direction. The angle error may be caused by the rotation of the patient's head position and the involuntary rotation of eyes. Phototherapeutic keratectomy can precisely cut the corneal tissue, and is often used in clinic to remove corneal scars or repair corneal surface morphology. In this study, the excimer laser therapeutic keratectomy mode was used to achieve accurate marking of the axis of astigmatism by setting the treatment laser parameters. With the help of the static cyclotorsion of the eye, the precise treatment of astigmatism could realize.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Astigmatism

Currently open trials in the same condition.

Other Tianjin Eye Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06694051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing